Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study | SpringerLink
Clinical effectiveness of seasonal influenza vaccine among adult cancer patients
Cancers | Free Full-Text | Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
Frontiers | miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | npj Breast Cancer
NBER on Twitter: "Sources of high end-of-life spending for cancer patients, from @danzeltzer, Liran Einav, Amy Finkelstein, Tzvi Shir, Salomon M. Stemmer, and Ran D. Balicer https://t.co/vyosdFbT3M https://t.co/VsajwVZKrx" / Twitter
Cetuximab intensifies cisplatin-induced testicular toxicity
WP2: Resilience Definition and operationalization
Collaterals
Fatal Noncutaneous Visceral Infection with Varicella-Zoster Virus in a Patient with Lymphoma after Autologous Bone Marrow Transp
A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells - Sofer - 2022 - The FASEB Journal - Wiley Online Library
Transnational cancer research lab | Felsenstein Medical Research Center
Patients with cancer achieve response to messenger RNA COVID-19 vaccine
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry | npj Breast Cancer
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) - Annals of Oncology
Trajectories of Injectable Cancer Drug Costs After Launch in the United States | Journal of Clinical Oncology
Salomon STEMMER | Tel Aviv University, Tel Aviv | TAU | Department of Oncology
Biomedicines | Free Full-Text | Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
Prof. Salomon Stemmer – CTG-Pharma
White Matter Changes in Patients with Breast Cancer Treated with High-Dose Chemotherapy and Autologous Bone Marrow Support
